Clinical Trial Update: Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) [Phase 3]

View source ↗

Summary

An update on the long-term extension of VAH631 in essential hypertension (extension from B1303), a Phase 3 trial sponsored by Novartis. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• VAH631

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED